19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
July 26, 2017 at 10:09 AM EDT
Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the ...